TP53 and myelodysplastic syndrome: It is reassuring that some efficacy of gilteritinib and venetoclax was also observed in an elderly patient with R/R TP53-mutated AML arising from preexisting MDS, who had complex karyotype alterations and a high TP53 variant allele frequency, both associated with poor prognosis [34].